ADVATE 250 IU, 500 IU, 1000 IU and 1500 IU powder and solvent for solution for injection 2 ml solvent - Baxject III
*Company:
Takeda Products Ireland LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 04 August 2023
File name
ie-spc-advate-2-ml-ref-attelica-proposed-clean-approved20July23.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 2 - Update to the specific activity limits
Date of revision updated
Updated on 08 July 2022
File name
ie-pl-advate-2-ml-emailupdate-june2022-clean.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 08 July 2022
File name
ie-spc-advate-2-ml-emailupdate-july2022-clean.pdf
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 08 July 2022
File name
ie-pl-advate-2-ml-emailupdate-june2022-clean.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 24 May 2022
File name
ie-spc-advate-2-ml-2mlstopperupdate-clean.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 11 April 2021
File name
Advate-ie-spc-2-ml-sodium-update-24-Feb-2021-clean.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
The main changes to the SmPC:
Section 2:
Excipients with known effect:
This medicinal product contains 0.45 mmol sodium (10 mg) per vial.
Section 4.4.
Excipient related considerations
Sodium
After reconstitution this medicinal product contains 0.45 mmol sodium (10 mg) per vial. To be taken into consideration by patients on a controlled sodium diet. This medicinal product contains 10 mg sodium per vial, equivalent to 0.5 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Section 10 date of revision: 24 February 2021
Updated on 11 April 2021
File name
Advate-ie-pl-2-ml-sodium-update-24-Feb-2021-clean.pdf
Reasons for updating
- Change to section 2 - excipient warnings
- Change to section 6 - date of revision
Updated on 15 April 2020
File name
Advate-ie-spc-2-ml-T-0106-02 April 2020-clean.pdf
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 15 April 2020
File name
Advate-ie-pl-2-ml-BJ-III-T-0106-April 2020-clean.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 04 March 2020
File name
ie-spc-2-ml-clean.pdf
Reasons for updating
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 02 March 2020
File name
ie-pl-5-ml-BJ-III-clean.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Updated on 17 September 2018
File name
ie-spc-007-8-9-10-17-18-19-20-2ml-6Sept18.pdf
Reasons for updating
- Change to section 5.1 - Pharmacodynamic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 5.1 (Pharmacodynamic properties), updated with the rewording of information regarding Immune Tolerance Induction (ITI)
Updated on 15 August 2018
File name
ie-pl-017-18-19-20-BJIII-2ml-14Jun18.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
Updated on 14 August 2018
File name
ie-pl-017-18-19-20-BJIII-2ml-14Jun18-clean.pdf
Reasons for updating
- Change to section 3 - use in children/adolescents
Updated on 14 August 2018
File name
ie-spc-007-8-9-10-17-18-19-20-2ml-14Jun18-clean.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.2 (Posology and method of administration), deletion of specific information that the use of 2 ml presentations has not been documented for paediatric subjects below 2 years of age.
Updated on 19 December 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 19 December 2017
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 9 - Date of first authorisation/renewal of the authorisation
Legal category:Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
- In section 4.4 (Special warnings and precautions for use), updated with scientific information on inhibitors.
- In section 4.8 (undesirable effects), updated with scientific information on inhibitors.
- In section 5.1 (Pharmacodynamic properties), removed scientific information on inhibitor development.
- In section 9 (DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION), updated with the latest renewal date.
Updated on 14 December 2017
File name
PIL_17212_842.pdf
Reasons for updating
- New PIL for new product
Updated on 14 December 2017
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
Updated on 06 July 2017
Reasons for updating
- New PIL for medicines.ie
Updated on 12 February 2016
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may not be renewed (A)